|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barollo S, Pezzani R, Cristiani A,
Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M,
Mucignat-Caretta C, Bulfone A, et al: Prevalence, tumorigenic role,
and biochemical implications of rare BRAF alterations. Thyroid.
24:809–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pelizzo MR, Boschin Merante I, Toniato A,
Pagetta C, Casal Ide E, Mian C and Rubello D: Diagnosis, treatment,
prognostic factors and long-term outcome in papillary thyroid
carcinoma. Minerva Endocrinol. 33:359–379. 2008.PubMed/NCBI
|
|
4
|
Rivera M, Ghossein RA, Schoder H, Gomez D,
Larson SM and Tuttle RM: Histopathologic characterization of
radioactive iodine-refractory fluorodeoxyglucose-positron emission
tomography-positive thyroid carcinoma. Cancer. 113:48–56. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosenbaum MA and McHenry CR: Contemporary
management of papillary carcinoma of the thyroid gland. Expert Rev
Anticancer Ther. 9:317–329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Learoyd DL, Messina M, Zedenius J and
Robinson BG: Molecular genetics of thyroid tumors and surgical
decision-making. World J Surg. 24:923–933. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Legakis I and Syrigos K: Recent advances
in molecular diagnosis of thyroid cancer. J Thyroid Res.
2011:3842132011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liou AK and Willison KR: Elucidation of
the subunit orientation in CCT (chaperonin containing TCP1) from
the subunit composition of CCT micro-complexes. EMBO J.
16:4311–4316. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yam AY, Xia Y, Lin HT, Burlingame A,
Gerstein M and Frydman J: Defining the TRiC/CCT interactome links
chaperonin function to stabilization of newly made proteins with
complex topologies. Nat Struct Mol Biol. 15:1255–1262. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brackley KI and Grantham J: Activities of
the chaperonin containing TCP-1 (CCT): Implications for cell cycle
progression and cytoskeletal organisation. Cell Stress Chaperones.
14:23–31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Won KA, Schumacher RJ, Farr GW, Horwich AL
and Reed SI: Maturation of human cyclin E requires the function of
eukaryotic chaperonin CCT. Mol Cell Biol. 18:7584–7589. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Camasses A, Bogdanova A, Shevchenko A and
Zachariae W: The CCT chaperonin promotes activation of the
anaphase-promoting complex through the generation of functional
Cdc20. Mol Cell. 12:87–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melville MW, McClellan AJ, Meyer AS,
Darveau A and Frydman J: The Hsp70 and TRiC/CCT chaperone systems
cooperate in vivo to assemble the von Hippel-Lindau tumor
suppressor complex. Mol Cell Biol. 23:3141–3151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X, Lin CY, Lei M, Yan S, Zhou T and
Erikson RL: CCT chaperonin complex is required for the biogenesis
of functional Plk1. Mol Cell Biol. 25:4993–5010. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boudiaf-Benmammar C, Cresteil T and Melki
R: The cytosolic chaperonin CCT/TRiC and cancer cell proliferation.
PLoS One. 8:e608952013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang X, Wang X, Cheng C, Cai J, He S,
Wang H, Liu F, Zhu C, Ding Z, Huang X, et al: Chaperonin containing
TCP1, subunit 8 (CCT8) is upregulated in hepatocellular carcinoma
and promotes HCC proliferation. Apmis. 122:1070–1079.
2014.PubMed/NCBI
|
|
19
|
Zhang Y, Wang Y, Wei Y, Wu J, Zhang P,
Shen S, Saiyin H, Wumaier R, Yang X, Wang C and Yu L: Molecular
chaperone CCT3 supports proper mitotic progression and cell
proliferation in hepatocellular carcinoma cells. Cancer Lett.
372:101–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui X, Hu ZP, Li Z, Gao PJ and Zhu JY:
Overexpression of chaperonin containing TCP1, subunit 3 predicts
poor prognosis in hepatocellular carcinoma. World J Gastroenterol.
21:8588–8604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qian EN, Han SY, Ding SZ and Lv X:
Expression and diagnostic value of CCT3 and IQGAP3 in
hepatocellular carcinoma. Cancer Cell Int. 16:552016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ribeiro FR, Meireles AM, Rocha AS and
Teixeira MR: Conventional and molecular cytogenetics of human
non-medullary thyroid carcinoma: Characterization of eight cell
line models and review of the literature on clinical samples. BMC
Cancer. 8:3712008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabra MM, Dominguez JM, Grewal RK, Larson
SM, Ghossein RA, Tuttle RM and Fagin JA: Clinical outcomes and
molecular profile of differentiated thyroid cancers with
radioiodine-avid distant metastases. J Clin Endocrinol Metab.
98:E829–E836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leitner A, Joachimiak LA, Bracher A,
Mönkemeyer L, Walzthoeni T, Chen B, Pechmann S, Holmes S, Cong Y,
Ma B, et al: The molecular architecture of the eukaryotic
chaperonin TRiC/CCT. Structure. 20:814–825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hansen WJ, Ohh M, Moslehi J, Kondo K,
Kaelin WG and Welch WJ: Diverse effects of mutations in exon II of
the von Hippel-Lindau (VHL) tumor suppressor gene on the
interaction of pVHL with the cytosolic chaperonin and
pVHL-dependent ubiquitin ligase activity. Mol Cell Biol.
22:1947–1960. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Melki R, Batelier G, Soulié S and Williams
RC Jr: Cytoplasmic chaperonin containing TCP-1: Structural and
functional characterization. Biochemistry. 36:5817–5826. 1997.
View Article : Google Scholar : PubMed/NCBI
|
